Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Trimurthi Ltd Stock Analysis

Small Cap
Evaluated by 59 users | BSE: 536565 | NSE: |
Trading

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Capital Employed 9.02%6.09%5.26%4.02%3.73%1.46%0.62%0.51%1.8%1.34%0.54%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 6.916.511.765.71.50.93.53.13.611
Y-o-Y Gr. Rt.-140.8%-29.2%-49%-3.7%-74.6%-36.3%277.4%-11.4%15.4%-71.3%-
Adjusted EPS (Rs.) 1.010.70.620.470.510.20.090.070.260.20.08-3.77
Y-o-Y Gr. Rt.--30.7%-11.4%-24.2%8.5%-60.8%-55%-22.2%271.4%-23.1%-60%-
Book Value per Share (Rs.) 11.311.6511.9913.6214.131414.1214.3114.614.8314.910.97
Adjusted Net Profit 0.70.50.40.40.40.20.10.10.20.20.1-3
Net Op. Cash Flow (Rs. Cr.) -0.6-0.6-0.4-3.50-0.42-1.11.1-0.41.2-
Debt to Cash Flow from Ops -0.39-0.26-0.21-0.021.26000000-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Trimurthi Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales -26.5%-6.7%-33.6%-71.3%
Adjusted EPS -21.4%-16.7%4.6%-60%
Book Value per Share 2.81.31.40.5
Share Price -12.1% -3% -1.7% -2.5%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Equity (%) 9.246.095.243.993.71.430.620.511.81.340.54-29.15
Operating Profit Margin (%) 9.172.136.2913.8615.4347.742.725.2115.35.02-27.62-306.78
Net Profit Margin (%) 9.962.863.576.417.2411.27.531.686.774.436.28-272.65
Debt to Equity 0.030.020.010.0100000000
Working Capital Days 2971352736456202,3643,3018591,0338902,8512112
Cash Conversion Cycle 804194155711452532851537962092
Loading price chart...
Entity Percentage Holding
Promoters 66.92%
Non-Institutions 33.08%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Trimurthi Ltd's earnings have declined by -16.7%, whereas share price has declined -3% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Trimurthi Ltd share price has declined -12.1% annually (CAGR) over the past ten years.

Data is not available for this company.

Trimurthi Drugs & Pharmaceuticals is an India-based company. The Company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products. The Company’s range of products include antibiotics, anti ulcer, anti inflammatory, antitussive/expectorant, cardiovascular, anti fungal, anti retroviral drugs, syrups and protein powder. The company since 1976 is built on the philosophy of commitment to quality and responsiveness.

2012 -The Company entered

Trimurthi Drugs & Pharmaceuticals is an India-based company. The Company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products. The Company’s range of products include antibiotics, anti ulcer, anti inflammatory, antitussive/expectorant, cardiovascular, anti fungal, anti retroviral drugs, syrups and protein powder. The company since 1976 is built on the philosophy of commitment to quality and responsiveness.

2012 -The Company entered into a Manufacturing Agreement with M/s. Bharat Parenterals Limited, Vadodara, Gujrat for exclusive manufacture of Company's 12 products for export. The Company entered into Distribution Agreement with Zyanya Global Pte Limited, Vietnam for selling the Company's Products in Vietnam.

Business areas of the company:

The company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products.

Divisions:

Pharma Business, Financial Services, Investment in Shares and Trading in Shares

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback